4 completed. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
Follow Refractory Marginal Zone Lymphoma: new trials by email Literature Review of Refractory Marginal Zone Lymphoma trials Research Report on Refractory Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2011-07-20 | 2021-10-04 |
Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Multiple Myeloma (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, B-Cell (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, B-Cell (3) · Leukemia, Lymphoid (3)
Bortezomib (1) · CT-P10 (1) · Calcium Dobesilate (1) · Carmustine (1) · Cytarabine (1) · Dexamethasone (1) · Etoposide (1) · Hematopoietic Stem Cell Transplantation (1) · Lenalidomide (1) · Melphalan (1) · Nivolumab (1) · Rituximab (1) · Sirolimus (1) · Stem Cell Transplantation (1) · auricularum (1)
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · University of Washington (1)
United States (4)
Kami Maddocks, MD (1) · Leonard T Heffner (1) · Loretta Nastoupil (1) · Rahul Banerjee, MD (1)
U10CA021115 (1), U10CA180820 (1)